EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Chemically Synthesized LRAD3‐D1 Interacts with N‐Terminal Domain of SARS‐CoV‐2 Spike Protein

Mrinmoy Jana, Rathina Delipan, Arighna Sarkar, Sreejith Raran-Kurussi, Rajesh P Ringe, Kalyaneswar Mandal iD

ChemBioChem · 2025

DOI: 10.1002/cbic.202500403 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemBioChem, 2025. Verfasst von Mrinmoy Jana und 5 weiteren Autor:innen. Beteiligte Einrichtung: Tata Institute of Fundamental Research Hyderabad, 36/p Gopanpally, Hyderabad, Telangana, 500046, India. Hauptthemen laut MEDLINE: Spike Glycoprotein, Coronavirus, SARS-CoV-2, Receptors, LDL. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Department of Atomic Energy, Government of India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Growing evidence of post‐COVID neurological complications, such as encephalopathy, neurodegeneration, and cognitive impairment, suggests severe acute respiratory syndrome‐related corona virus 2 (SARS‐CoV‐2) viral infection into the central nervous system (CNS). Therefore, understanding the mechanisms of viral entry into the CNS, where human angiotensin‐converting enzyme 2 (ACE2) is barely expressed, is critical for addressing the neurological consequences of COVID‐19. Importantly, the low‐density lipoprotein receptor class A domain containing 3 (LRAD3) is overexpressed in brain cells, suggesting a possible ACE2‐independent alternate pathway of viral entry into brain cells. Herein, the interaction of the chemically synthesized LRAD3 domains with SARS‐CoV‐2 spike protein is reported. It is observed that the extracellular domains of LRAD3 depend on calcium for proper folding and maintaining their structural integrity. The results reveal that domain 1 of LRAD3, which is most accessible from the cell surface, engages with the N‐terminal domain of the viral spike protein. These findings open up possibilities to develop new therapeutic strategies targeting ACE2 independent viral entry pathways.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spike Glycoprotein, CoronavirusSARS-CoV-2Receptors, LDLHumansProtein DomainsProtein BindingAngiotensin-Converting Enzyme 2COVID-19

Stichwörter der Autor:innen

LRAD3 ectodomainSARS‐CoV‐2 entryneurological disorderspeptide synthesis

Substanzen

Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Receptors, LDLAngiotensin-Converting Enzyme 2ACE2 protein, human

Autor:innen und Institutionen

  • Tata Institute of Fundamental Research Hyderabad, 36/p Gopanpally, Hyderabad, Telangana, 500046, India.
  • Institute of Microbial Technology, Council of Scientific and Industrial Research, Sector 39-A, Chandigarh, 160036, India.

ORCID-Profile: Kalyaneswar Mandal

Förderung

  • Department of Atomic Energy, Government of India

Zitieren

APA

Jana, M., Delipan, R., Sarkar, A., Raran-Kurussi, S., Ringe, R. P., & Mandal, K. (2025). Chemically Synthesized LRAD3‐D1 Interacts with N‐Terminal Domain of SARS‐CoV‐2 Spike Protein. ChemBioChem. https://doi.org/10.1002/cbic.202500403

Vancouver

Jana M, Delipan R, Sarkar A, Raran-Kurussi S, Ringe RP, Mandal K. Chemically Synthesized LRAD3‐D1 Interacts with N‐Terminal Domain of SARS‐CoV‐2 Spike Protein. ChemBioChem. 2025. doi:10.1002/cbic.202500403

BibTeX
@article{Jana2025,
  author = {Jana, Mrinmoy and Delipan, Rathina and Sarkar, Arighna and Raran-Kurussi, Sreejith and Ringe, Rajesh P and Mandal, Kalyaneswar},
  title = {Chemically Synthesized LRAD3‐D1 Interacts with N‐Terminal Domain of SARS‐CoV‐2 Spike Protein},
  journal = {ChemBioChem},
  year = {2025},
  doi = {10.1002/cbic.202500403}
}
Kostenlos starten →